Drug Profile


Alternative Names: AAV-CYP46A1; AAV-mediated CYP46A1 gene therapy - BrainVectis; BV-CYP01

Latest Information Update: 28 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BrainVectis
  • Class Antidementias; Gene therapies
  • Mechanism of Action Cholesterol 24-hydroxylase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Alzheimer's disease; Huntington's disease; Spinocerebellar degeneration

Most Recent Events

  • 28 Mar 2018 BrainVectis has patent protection for BV CYP01 for Alzheimer's disease and Huntington's disease in USA and Europe
  • 28 Mar 2018 Preclinical trials in Spinocerebellar degeneration in France (Parenteral)
  • 11 Oct 2017 Preclinical trials in Alzheimer's disease in France (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top